2023
Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
Greene S, Velazquez E, Anstrom K, Clare R, DeWald T, Psotka M, Ambrosy A, Stevens G, Rommel J, Alexy T, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Eisenstein E, Mentz R, Investigators O. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. Circulation 2023, 148: 124-134. PMID: 37212600, PMCID: PMC10524905, DOI: 10.1161/circulationaha.123.064842.Peer-Reviewed Original ResearchMeSH KeywordsFurosemideHeart FailureHumansQuality of LifeSodium Potassium Chloride Symporter InhibitorsStroke VolumeTorsemideConceptsPatient Health Questionnaire-2Prespecified secondary end pointsQuality of lifeEffects of torsemideSecondary end pointsHeart failurePatient-reported outcomesKansas City Cardiomyopathy Questionnaire clinical summary scoreNew York Heart Association classPatient Health Questionnaire-2 scoreEnd pointQuestionnaire-2Loop diuretic agentsLoop diuretic useProportion of patientsBaseline health statusClinical summary scoreEjection fraction phenotypeSignificant differencesDiuretic strategyTorsemide groupCause hospitalizationCause mortalityDiuretic usePrimary therapyEffect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure
Mentz R, Anstrom K, Eisenstein E, Sapp S, Greene S, Morgan S, Testani J, Harrington A, Sachdev V, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Velazquez E, Adams K, Bhatt K, DeWald T, Axsom K, Murthy S, Rich J, Testani J, Smith B, Vader J, McCulloch M, Skopicki H, Psotka M, Heroux A, Lala-Trindade A, Stevens G, Tang W, Lev Y, William P, Eberly A, Gottleib S, Haught W, Grafton G, Larned J, Tejwani L, Mody F, Krim S, Robinson M, Fang J, Adler A, Bell A, Banerjee D, Ruiz Duque E, Mizyed A, Rommel J, Arhinful J, Goyal P, Hall M, Hummel S, Shetty S, Haas D, Vilaro J, Alexy T, Herre J, Clark J, Ambrosy A, Gaglianello N, Ramasubbu K, Meadows J, Tabtabai S, Sherwood M, Hasni S, D'Urso M, Muneer B, Dunlap S, Davis W, Friedman D, Guglin M, Ferguson A, Abbate A, Smart F. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA 2023, 329: 214-223. PMID: 36648467, PMCID: PMC9857435, DOI: 10.1001/jama.2022.23924.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleFurosemideHeart FailureHospitalizationHumansMaleMiddle AgedPatient DischargeSodium Potassium Chloride Symporter InhibitorsTorsemideTreatment OutcomeConceptsCause mortalityHeart failureTorsemide groupFurosemide groupTotal hospitalizationsCause hospitalizationEffects of torsemideDiuretic strategyPrespecified subgroupsSecondary outcomesEjection fractionMedian agePrimary outcomeHospitalizationMAIN OUTCOMEPatientsFurosemideMortalityMonthsTorsemidePrimary hypothesisSignificant differencesFinal dateOutcomesTrials
2015
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)
Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). The American Journal Of Cardiology 2015, 117: 404-411. PMID: 26704029, PMCID: PMC4718787, DOI: 10.1016/j.amjcard.2015.10.059.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedCause of DeathDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesFurosemideGlobal HealthHeart FailureHospitalizationHumansMaleMiddle AgedRetrospective StudiesSodium Potassium Chloride Symporter InhibitorsStroke VolumeSulfonamidesSurvival RateTorsemideTreatment OutcomeConceptsHeart failureChoice of diureticAcute heart failureDecompensated heart failureNatriuretic peptide levelsLow ejection fractionComparative effectiveness trialHF hospitalizationBlood pressureEjection fractionUnadjusted analysesAcute studyClinical effectivenessEffectiveness trialPeptide levelsPatientsFurosemideSimilar outcomesInverse probabilityPotential pharmacologicTorsemideDiureticsMortalityTrialsFailureTorsemide Versus Furosemide in Heart Failure Patients
Mentz RJ, Buggey J, Fiuzat M, Ersbøll MK, Schulte PJ, DeVore AD, Eisenstein EL, Anstrom KJ, O'Connor C, Velazquez EJ. Torsemide Versus Furosemide in Heart Failure Patients. Journal Of Cardiovascular Pharmacology 2015, 65: 438-443. PMID: 25945862, PMCID: PMC4423558, DOI: 10.1097/fjc.0000000000000212.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedComorbidityDatabases, FactualFemaleFurosemideHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedNorth CarolinaRetrospective StudiesRisk FactorsSex FactorsSodium Potassium Chloride Symporter InhibitorsSulfonamidesTertiary Care CentersTorsemideTreatment OutcomeUltrasonographyConceptsHeart failure patientsFailure patientsEffects of torsemideFurosemide-treated patientsMore comorbiditiesCause mortalityBaseline characteristicsProspective trialHeart failureLoop diureticsResidual confoundingPatientsDuke HospitalFurosemideRisk adjustmentTorsemideMortalityLab databaseComorbiditiesDiureticsHospitalTrialsA reappraisal of loop diuretic choice in heart failure patients
Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM. A reappraisal of loop diuretic choice in heart failure patients. American Heart Journal 2015, 169: 323-333. PMID: 25728721, PMCID: PMC4346710, DOI: 10.1016/j.ahj.2014.12.009.Peer-Reviewed Original ResearchMeSH KeywordsChoice BehaviorFibrosisFurosemideHeartHeart FailureHumansMyocardiumPractice Patterns, Physicians'Renin-Angiotensin SystemSodium Potassium Chloride Symporter InhibitorsSulfonamidesTorsemideUp-RegulationVentricular Dysfunction, LeftConceptsHeart failure patientsHeart failureFailure patientsLoop diureticsNew York Heart Association functional classPlasma brain natriuretic peptide levelsYork Heart Association functional classBrain natriuretic peptide levelsHeart failure severityNatriuretic peptide levelsTranscardiac extractionAldosterone secretionAldosterone systemDiuretic useVentricular functionFurosemide useSymptom managementPharmacologic differencesCardiac fibrosisSurrogate markerMEDLINE searchPeptide levelsControl trialEconomic burdenFurosemide
2011
Diuretic Strategies in Patients with Acute Decompensated Heart Failure
Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart B, Mascette AM, Braunwald E, O'Connor CM. Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal Of Medicine 2011, 364: 797-805. PMID: 21366472, PMCID: PMC3412356, DOI: 10.1056/nejmoa1005419.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedArea Under CurveCreatinineDiureticsDouble-Blind MethodDrug Administration ScheduleDyspneaFemaleFurosemideHeart FailureHumansInfusions, IntravenousInjections, IntravenousIntention to Treat AnalysisKaplan-Meier EstimateMaleMiddle AgedSodium Potassium Chloride Symporter InhibitorsConceptsAcute decompensated heart failureDecompensated heart failurePatient global assessmentHeart failureCreatinine levelsContinuous infusionHigh-dose strategyGlobal assessmentRenal functionMean changeLow doseHigh doseSignificant differencesCoprimary end pointsSerum creatinine levelsHigh-dose groupLow-dose strategyVisual analog scaleComparison of BolusDiuretic strategyDiuretic therapyTransient worseningGreater diuresisDose adjustmentLoop diuretics